Charles River Labs Intl Stock
Price
Target price
€133.15
€133.15
-1.700%
-
-1.700%
€170.62
15.07.25 / Tradegate
WKN: 939391 / Symbol: CRL / Name: Charles River Lb / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Charles River Labs Intl Stock
We can see a decrease in the price for Charles River Labs Intl. Compared to yesterday it has lost €0.000 (-1.700%).
Currently there is a rather positive sentiment for Charles River Labs Intl with 11 Buy predictions and 3 Sell predictions.
As a result the target price of 170 € shows a positive potential of 27.68% compared to the current price of 133.15 € for Charles River Labs Intl.
Pros and Cons of Charles River Labs Intl in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Charles River Labs Intl vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Charles River Labs Intl | -1.700% | -1.443% | 2.898% | -32.922% | -24.668% | -40.425% | -21.676% |
| Ironwood Pharmaceuticals | -0.790% | -0.794% | 10.619% | -89.496% | -85.119% | -94.568% | -92.938% |
| Arrowhead Pharmaceuticals Inc. | -3.260% | 1.604% | 11.596% | -42.579% | -17.789% | -64.169% | -63.991% |
| Novocure Ltd | 2.110% | -3.079% | -7.888% | -12.189% | -50.275% | -79.861% | -74.041% |
Comments
Charles River Laboratories International, Inc. (NYSE: CRL) had its price target raised by analysts at Evercore ISI from $170.00 to $180.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International, Inc. (NYSE: CRL) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating. They now have a $200.00 price target on the stock, up previously from $150.00.
Show more
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International, Inc. (NYSE: CRL) was upgraded by analysts at Redburn Atlantic from a "neutral" rating to a "buy" rating. They now have a $182.00 price target on the stock, down previously from $188.00.
Show more
Ratings data for CRL provided by MarketBeat
News
Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2025 financial results on Wednesday, August 6th, before the market opens. A conference call has been scheduled
Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a recycling program, developed in partnership with international recycling leader TerraCycle®, to give new life to
Charles River Laboratories to Present at William Blair and Jefferies Conferences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the William Blair 45th Annual Growth Stock Conference on Tuesday, June 3rd, at 10:00 a.m. CT